Pay in 4 interest-free payments of $5.98 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
A consistent schedule helps your body adapt to regular dosing and makes remembering much easier
ATTAIN-1 (NCT05869903) was a Phase III, 72-week, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of orforglipron at various doses to placebo in adults with obesity, or overweight with at least one of the following comorbidities: hypertension, dyslipidemia, obstructive sleep apnea or cardiovascular disease, who did not have diabetes
Karademir, E
With needleless systems, the stress and anxiety often associated with injections can be significantly reduced, potentially improving treatment adherence and health outcomes
US$ 25.33
US$ 27.81
US$ 21.60
